HC Wainwright Issues Pessimistic Outlook for CNTB Earnings

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) – Equities research analysts at HC Wainwright reduced their Q2 2026 earnings per share (EPS) estimates for Connect Biopharma in a research note issued to investors on Tuesday, May 12th. HC Wainwright analyst B. Folkes now anticipates that the company will earn ($0.31) per share for the quarter, down from their previous forecast of ($0.24). The consensus estimate for Connect Biopharma’s current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Connect Biopharma’s Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.22) EPS, FY2026 earnings at ($1.12) EPS, FY2027 earnings at ($0.98) EPS, FY2028 earnings at ($0.79) EPS, FY2029 earnings at ($0.49) EPS and FY2030 earnings at ($0.09) EPS.

Connect Biopharma (NASDAQ:CNTB) last released its earnings results on Tuesday, May 12th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.05). The business had revenue of $0.02 million for the quarter.

A number of other analysts also recently weighed in on CNTB. BTIG Research reissued a “buy” rating and set a $10.00 target price on shares of Connect Biopharma in a research report on Tuesday, March 31st. Weiss Ratings reissued a “sell (d)” rating on shares of Connect Biopharma in a research report on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.67.

Connect Biopharma Stock Performance

NASDAQ:CNTB opened at $2.45 on Thursday. The company has a market capitalization of $138.47 million, a PE ratio of -2.13 and a beta of -0.21. The company has a 50 day simple moving average of $2.74 and a two-hundred day simple moving average of $2.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.74 and a current ratio of 3.74. Connect Biopharma has a fifty-two week low of $0.70 and a fifty-two week high of $3.82.

Institutional Trading of Connect Biopharma

Large investors have recently modified their holdings of the stock. XTX Topco Ltd acquired a new stake in shares of Connect Biopharma during the 2nd quarter worth approximately $29,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Connect Biopharma during the 4th quarter worth approximately $36,000. HRT Financial LP grew its position in shares of Connect Biopharma by 60.5% during the 4th quarter. HRT Financial LP now owns 16,785 shares of the company’s stock worth $47,000 after buying an additional 6,328 shares during the period. Persistent Asset Partners Ltd acquired a new stake in shares of Connect Biopharma during the 4th quarter worth approximately $76,000. Finally, Royal Bank of Canada acquired a new stake in shares of Connect Biopharma during the 4th quarter worth approximately $114,000. Institutional investors and hedge funds own 58.72% of the company’s stock.

Insider Activity at Connect Biopharma

In related news, Director James Huang acquired 1,160,000 shares of Connect Biopharma stock in a transaction dated Tuesday, March 31st. The stock was bought at an average price of $3.45 per share, with a total value of $4,002,000.00. Following the transaction, the director directly owned 13,160,000 shares in the company, valued at $45,402,000. This represents a 9.67% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 22.60% of the stock is currently owned by company insiders.

About Connect Biopharma

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.